Drug Database
Back to search

Netherlands· NL-bffe96385f1f

Ayvakyt 50 mg filmomhulde tabletten

A avapritinib product containing avapritinib, registered in Netherlands by Blueprint Medicines (Netherlands) B.V.. The same ATC class is registered in 14 of our 19 countries.

ATC L01EX18

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedAyvakyt 50 mg filmomhulde tablettenATCL01EX18REGISTER NO.NL-bffe96385f1fPACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about avapritinibAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Avapritinib is registered in 14 of 19 countries.

Countries holding a registration under ATC L01EX18 (avapritinib), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 9 of them publish a price we can compare per daily dose
Search avapritinib products by name

Avapritinib · ATC L01EX18

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of avapritinib costs, country by country.

Normalised to the WHO defined daily dose (0.3 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Avapritinib · price per daily dose (0.3 g)

USD · FX 28 Sept 2026

  • FR France$1.93
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
AVAPRITINIB
Manufacturer
Blueprint Medicines (Netherlands) B.V.
Country
Netherlands (NL)
ATC code
L01EX18
ATC class
Avapritinib
Defined daily dose
0.3 g, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/20/1473

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

226 interactions on record for avapritinib.

Graded by severity as the source publishes them — 142 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check avapritinib against other medicinesHow interaction checks work

Avapritinib · interactions on record

226 records

  • 142 severe
  • 84 moderate

Most severe, free to view

  • AprepitantA04AD12severe
  • DicoumarolB01AA01severe
  • WarfarinB01AA03severe
  • HeparinB01AB01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Avapritinib in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All avapritinib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Ayvakyt
  • Liechtenstein · Ayvakyt
  • Norway · Ayvakyt

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/64d97efa-4850-4f44-9433-215e29137c9c
GET /v1/drugs/64d97efa-4850-4f44-9433-215e29137c9c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/ayvakyt-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Avapritinib",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp128019",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "COPOVIDON (E 1208)",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "MACROGOL 3350",
    "MAGNESIUMSTEARAAT (E 470b)",
    "POLYVINYLALCOHOL (E 1203)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "AVAPRITINIB"
  ],
  "leaflet_url": null,
  "authorised_at": "2022/03/25",
  "procedure_number": "EMEA/H/C/005208",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/20/1473",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about avapritinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console